| 2024-04-22 | +0.69 % |
|
| 2024-04-18 | -0.64 % |
|
| 2024-04-17 | +0.54 % |
|
| 2024-04-15 | -0.12 % |
|
| 2024-04-05 | +2.1 % |
|
| 2024-03-28 | -0.03 % |
- The article discusses the increase in institutional investors' stake in Eli Lilly and Company (LLY) by 2.8% in the fourth quarter, with various funds adding or reducing their positions, leading to Eli Lilly & Co (LLY) stock going down by -0.03%, possibly affected by these changes in stakeholding.
- The article discusses RNC Capital Management LLC cutting its position in Eli Lilly and Company (NYSE:LLY) by 0.7% in the fourth quarter, selling 103 shares, leading to a 0.03% decrease in the stock. The decrease in Eli Lilly & Co (LLY) stock might be attributed to the selling off of some shares by RNC Capital Management LLC, as well as insider selling activities impacting the stock price.
- The article discusses how S.A. Mason LLC grew its position in shares of Eli Lilly and Company while other institutional investors made adjustments to their positions in the company, most notably, a major shareholder, Lilly Endowment Inc, selling a significant amount of shares. Eli Lilly & Co (LLY) stock went down likely due to this selling activity by major stakeholders and institutional investors restructuring their positions.
|
| 2024-03-27 | +0.42 % |
|
| 2024-03-26 | +0.23 % |
|
| 2024-03-25 | +0.33 % |
- The article discusses how Tributary Capital Management LLC reduced its stake in Eli Lilly and Company (LLY) by 12.5% in the 4th quarter of the last year, along with other large investors who have made modifications in their holdings. The stock of Eli Lilly and Company (LLY) was observed to be up by 0.33%, and the reason for this increase could be attributed to various factors such as improved quarterly earnings results, positive outlook by research firms with increased target prices, and insider selling activities.
- The article discusses how ZRC Wealth Management LLC purchased new shares of Eli Lilly and Company (LLY) and several other institutional investors have adjusted their holdings in the company, driving its stock up by 0.33%. Eli Lilly & Co.'s stock goes up due to increased institutional investments, positive quarterly earnings report, and favorable analyst ratings, predicting strong future performance.
- The article discusses Eli Lilly & Co (LLY) stock, which saw a 0.33% increase, with the stock being lifted by Kingswood Wealth Advisors LLC by 152.7% due to their increased position in the company, alongside other large institutional investments, leading to analysts issuing favorable ratings and setting increased price targets, and with the company's latest quarterly earnings report exceeding expectations, driving the stock's value up; the increase in institutional investments, positive analyst ratings, and strong financial performance are potential drivers behind the rise in Eli Lilly & Co's stock price.
|
| 2024-03-21 | -0.34 % |
- The article discusses the YWCA Women's Empowerment Fund reaching $50 million in Assets Under Management and highlights its focus on promoting gender equity. Eli Lilly & Co (LLY) stock went down possibly due to broader market trends, specific company performance, or other external factors affecting the healthcare sector.
- Summary: The article provides insights into the healthcare sector, focusing on challenges faced by investors in 2023 and expected changes in 2024. It highlights the performance of various healthcare sub-sectors, mentioning key companies like Eli Lilly & Company (LLY) and Novo Nordisk A/S. Additionally, it discusses the impact of COVID-19, advances in healthcare technologies like AI, efforts to address health disparities, and strategies to control healthcare costs.
Reason for Eli Lilly & Company (LLY) Stock Decline: Eli Lilly & Company (LLY) stock went down due to an announcement by Novo Nordisk A/S regarding cardiovascular benefits in their GLP-1 SELECT trial, which triggered a sell-off across the pharmaceutical sub-sector, erasing gains and resulting in negative returns.
|
| 2024-03-20 | +0.01 % |
|
| 2024-03-19 | +1.33 % |
|
| 2024-03-14 | +0.38 % |
|
| 2024-03-13 | +0.38 % |
|
| 2024-03-11 | -3.64 % |
|
| 2024-03-08 | -2.31 % |
- The article discusses 10 biotech stocks with huge potential, indicating a positive outlook for the industry with recent optimism and market trends leading to a rally, but last night, Eli Lilly & Co (LLY) stock was down by -2.31%; the decline in LLY stock may be due to various factors such as market fluctuations, investor sentiment, or company-specific news affecting its performance.
- Eli Lilly & Co (LLY) stock was down 2.31% as the FDA requested more information about its Alzheimer's treatment, donanemab, leading to a delay in its release, causing investors to be concerned about the uncertainty surrounding the drug's approval.
- The FDA has delayed a decision on Eli Lilly & Co's Alzheimer's drug, donanemab, causing the stock to drop over 10% as concerns arose about the drug's safety and efficacy, mainly due to the occurrence of amyloid-related imaging abnormalities (ARIA) and the unique trial design allowing participants to stop using the drug based on their amyloid plaque levels.
|
| 2024-03-07 | +0.05 % |
|
| 2024-03-06 | +0.28 % |
|
| 2024-03-05 | -1.85 % |
|
| 2024-03-01 | +3.77 % |
|
| 2024-02-29 | -0.52 % |
|
| 2024-02-28 | -0.96 % |
|
| 2024-02-27 | -0.9 % |
|
| 2024-02-26 | +0.31 % |
|
| 2024-02-23 | -0.01 % |
|
| 2024-02-22 | +3.18 % |
|
| 2024-02-20 | -3.38 % |
|
| 2024-02-16 | +3.2 % |
|
| 2024-02-15 | +0.06 % |
- The article discusses how research analysts, including Cantor Fitzgerald and Barclays, have reaffirmed their overweight ratings on Eli Lilly and Company (LLY) stock, with a price target of $815. The stock recently went up by 0.06%. The increase in the stock price could be attributed to the positive earnings results announced by the company, with higher-than-expected EPS and revenue. Additionally, institutional investors have made significant changes to their positions in LLY, further boosting the stock.
- The article states that Eli Lilly & Co stock has increased by 0.06% and it is speculated that the launch of their obesity drug, Mounjaro (tirzepatide), in Britain is the reason behind the increase.
- The article discusses the projected growth of the fibromyalgia treatment market, which is expected to reach $4.6 billion by 2032, leading to an increase in demand for diverse and advanced treatment options. It also mentions that Eli Lilly & Co (LLY) recently announced positive clinical results for a treatment related to hearing loss. While the article does not directly state the reason for Eli Lilly & Co's stock going up, the positive clinical results could have contributed to investor optimism and confidence in the company's future prospects.
|
| 2024-02-13 | +0.77 % |
|
| 2024-02-09 | +0.61 % |
|
| 2024-02-08 | +1.42 % |
|
| 2024-02-07 | +2.89 % |
|
| 2024-02-06 | -0.17 % |
|
| 2024-02-02 | +1.09 % |
|
| 2024-01-31 | +0.1 % |
|
| 2024-01-30 | |
|
| 2024-01-26 | +1.85 % |
|
| 2024-01-25 | -0.96 % |
|
| 2024-01-22 | +0.37 % |
|
| 2024-01-18 | -0.88 % |
|
| 2024-01-17 | -0.89 % |
|
| 2024-01-16 | -1.3 % |
|
| 2024-01-10 | +0.75 % |
|
| 2024-01-05 | +0.66 % |
|
| 2024-01-04 | -0.52 % |
|
| 2024-01-03 | +4.31 % |
|
| 2023-12-29 | +0.36 % |
|
| 2023-12-27 | +1.9 % |
|
| 2023-12-22 | -0.28 % |
|
| 2023-12-20 | -1.66 % |
|
| 2023-12-19 | +0.01 % |
|
| 2023-12-18 | +1.35 % |
|
| 2023-12-14 | -3.99 % |
|
| 2023-12-13 | +2.18 % |
|
| 2023-12-11 | -2.34 % |
|
| 2023-12-05 | +0.42 % |
|
| 2023-12-04 | +0.28 % |
- Roche Holding AG has agreed to acquire Carmot Therapeutics Inc. for up to $3.1 billion, signaling a push into the weight-loss treatment market and potentially competing with Novo Nordisk and Eli Lilly & Co., which have drugs in that space. The weight-loss market is estimated to reach $100 billion by 2030, and Roche is joining other pharmaceutical giants such as Pfizer and AstraZeneca in developing treatments in this area. The deal will provide Roche with three experimental medicines for obesity and diabetes, with the lead drug ready to enter the second stage of clinical testing. The transaction is expected to close in the first quarter of 2024.
- The article discusses the increasing competition among drugmakers to capture a share of the obesity treatment market, with companies like Novo Nordisk and Eli Lilly already offering highly sought-after treatments, and the recent entry of Roche through its acquisition of Carmot Therapeutics. The estimated worth of the obesity treatment market is $100 billion by the end of the decade. Eli Lilly's stock went up because its weight-loss therapy, Zepbound, received approval from U.S. and UK regulators, making it a new competitor to Novo Nordisk's Wegovy.
- Eli Lilly & Co (LLY) stock went up by 0.28% yesterday, outperforming its competitors, including Pfizer Inc (PFE), Johnson & Johnson (JNJ), and Abbott Laboratories (ABT), with trading volume higher than its 50-day average volume, likely due to positive market conditions and investor interest.
|
| 2023-12-01 | -1.18 % |
|
| 2023-11-30 | -0.14 % |
|
| 2023-11-29 | +0.04 % |
|
| 2023-11-28 | +0.01 % |
|
| 2023-11-27 | -1.59 % |
|
| 2023-11-24 | +1.01 % |
|
| 2023-11-22 | +0.42 % |
|
| 2023-11-17 | +0.5 % |
|
| 2023-11-13 | +2.51 % |
- Eli Lilly & Co (LLY) stock went up by 2.51% last night. The article does not provide an explanation for why the stock went up, as it primarily focuses on the performance and clinical trial data of Verve Therapeutics Inc., whose shares fell 40% premarket.
- The stock price of Eli Lilly & Co (LLY) went up 2.51% last night; however, the article is about a study conducted by researchers at Johns Hopkins Medicine on lupus, an autoimmune condition, and the frequency of the disease in females. The researchers discovered that a piece of genetic material called X-inactive specific transcript (XIST), found only in women, plays a role in promoting autoimmunity and increasing susceptibility to lupus. This discovery may lead to the development of new therapies targeting the XIST-TLR7 pathway and provide a better understanding of the disease's origins.
- Verve Therapeutics saw its stock plummet after disappointing results from early-stage clinical trials for their cholesterol treatment, VERVE-101, causing concerns over competition and potential liver damage. Despite this, Eli Lilly & Co., which recently acquired the rights to Verve's gene-editing product, has seen its stock rise, highlighting the volatile nature of biotechnology investments.
|
| 2023-11-10 | +1.08 % |
|
| 2023-11-09 | -4.49 % |
|
| 2023-11-08 | +3.2 % |
- Rigel Pharmaceuticals reported significant growth in sales for its approved products, TAVALISSE and REZLIDHIA, in the third quarter of 2023, and highlighted its ongoing development programs and strategic plans for the future, including a focus on hematology oncology products. The company aims to reach financial breakeven and become self-sustaining, with potential growth in REZLIDHIA sales and opportunities for label expansion. Rigel's stock has fared poorly over the last month, but the company's financial stability and promising revenue growth may be of interest to investors.
- The article provides a summary of a recent earnings call by Inspire Medical Systems, reporting a 40% increase in revenue driven by increased usage and new facilities, along with plans for further expansion and product development, although challenges in Europe related to medical device regulation may impact fourth-quarter revenue.
- The article discusses the performance and investment strategy of the BNY Mellon Dynamic Value Fund, which has been successful over the years. The fund managers highlight three stocks - JPMorgan Chase & Co., Medtronic PLC, and Constellation Energy Corp. - as standout bargains for investors. They believe these stocks offer value and have the potential for growth. As for why Eli Lilly & Co. (LLY) stock went up, the article does not provide any specific information about the company or its stock performance.
|
| 2023-11-06 | +4.82 % |
|
| 2023-11-02 | +4.66 % |
|
| 2023-10-31 | -2.08 % |
|
| 2023-10-30 | +0.98 % |
- The article discusses the mixed performance of Asian share markets due to fears of wider conflict in Gaza and upcoming central bank meetings in the US, UK, and Japan, with Eli Lilly & Co among the companies reporting earnings this week; however, the specific reason for the increase in Eli Lilly & Co (LLY) stock is not mentioned in the article.
- Fuller Seminary has received a $1.25 million grant from Lilly Endowment Inc. to document, model, and cultivate compelling preaching in four ethnic contexts (Korean, Latino/a, Black, and Asian American), which aims to inspire and guide people to know and love God more fully, leading to the increase in Eli Lilly & Co (LLY) stock.
|
| 2023-10-25 | -1.01 % |
|
| 2023-10-24 | +2.74 % |
|
